Michela Iacobellis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Michela Iacobellis has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Giuseppe Giuffrè
Laboratory of Molecular Pathologic Anatomy, Department of Human Pathology in Adult and Developmental Age "G. Barresi", University of Messina, Messina, Italy
2 shared publications - Angela Simone
Laboratory of Molecular Biology Applied to Pathologic Anatomy, Department of Human Pathology in Adult and Developmental Age “G. Barresi”, University of Messina, Messina, Italy
1 shared publication - Angelica Bianco
Istituto Zooprofilattico Sperimentale della Puglia e della Basilicata, Via Manfredonia 20, 71121 Foggia, Italy
1 shared publication - Antonio Parisi
Istituto Zooprofilattico Sperimentale della Puglia e della Basilicata, Via Manfredonia 20, 71121 Foggia, Italy
1 shared publication - Cecilia Violante
Cytopathology Department of the Hospital Di Venere, Bari, Italy
1 shared publication - Domenico Simone
Istituto Zooprofilattico Sperimentale della Puglia e della Basilicata, 71121 Foggia, Italy
1 shared publication
Latest Publications
- Open Access
Relative HPV Viral Load Measured by ΔCt for Risk Stratification in Cervical Cancer Screening
Background/Objectives: Human papillomavirus (HPV) testing is widely used in cervical cancer screening because of its high sensitivity, although its limited specificity requires effective triage strategies. This study aimed to evaluate the association between relative viral load (RVL) and cervical lesion severity, focusing on HPV-positive women with non-high-grade cytology. Methods: The study included 997 women with histological outcomes from a cohort of 2765 HPV-positive individuals identified among 37,030 women screened in the Bari metropolitan area (Italy) using a real-time HPV-DNA test. Associations between RVL, estimated using the ΔCt method, and lesion severity were assessed using histological and cytological classifications. Logistic regression models evaluated the independent effect of RVL, adjusting for age and HPV detection channel. Results: Lower ΔCt values (indicating higher RVL) were significantly associated with high-grade lesions (CIN2+) (OR = 0.91, 95% CI: 0.89–0.94, p < 0.001). The association was observed for HPV16 and the pooled 12-high-risk HPV detection channel, while no significant association was observed for HPV18. A similar association was observed when cytological classification was used as the outcome. Age showed a modest effect, with reduced odds of high-grade lesions observed in women aged ≥50 years. Among women with non-high-grade cytology who subsequently underwent histological assessment, 17.6% had underlying CIN2+, and RVL remained significantly associated with lesion severity in this subgroup. However, ΔCt showed only modest discrimination for high-grade lesions [AUC = 0.643 (95% CI: 0.605–0.681)]. Conclusions: Higher HPV RVL is associated with increased lesion severity, particularly for HPV16 and the pooled 12-high-risk detection channel, but not for HPV18. Given its modest standalone discriminatory performance and the selected nature of the histologically verified cohort, ΔCt should be considered an exploratory marker rather than a validated triage tool. Prospective validation is required to determine whether it provides incremental clinical value.
Open AccessRelative HPV Viral Load Measured by ΔCt for Risk Stratification in Cervical Cancer Screening
Background/Objectives: Human papillomavirus (HPV) testing is widely used in cervical cancer screening because of its high sensitivity, although its limited specificity requires effective triage strategies. This study aimed to evaluate the association between relative viral load (RVL) and cervical lesion severity, focusing on HPV-positive women with non-high-grade cytology. Methods: The study included 997 women with histological outcomes from a cohort of 2765 HPV-positive individuals identified among 37,030 women screened in the Bari metropolitan area (Italy) using a real-time HPV-DNA test. Associations between RVL, estimated using the ΔCt method, and lesion severity were assessed using histological and cytological classifications. Logistic regression models evaluated the independent effect of RVL, adjusting for age and HPV detection channel. Results: Lower ΔCt values (indicating higher RVL) were significantly associated with high-grade lesions (CIN2+) (OR = 0.91, 95% CI: 0.89–0.94, p < 0.001). The association was observed for HPV16 and the pooled 12-high-risk HPV detection channel, while no significant association was observed for HPV18. A similar association was observed when cytological classification was used as the outcome. Age showed a modest effect, with reduced odds of high-grade lesions observed in women aged ≥50 years. Among women with non-high-grade cytology who subsequently underwent histological assessment, 17.6% had underlying CIN2+, and RVL remained significantly associated with lesion severity in this subgroup. However, ΔCt showed only modest discrimination for high-grade lesions [AUC = 0.643 (95% CI: 0.605–0.681)]. Conclusions: Higher HPV RVL is associated with increased lesion severity, particularly for HPV16 and the pooled 12-high-risk detection channel, but not for HPV18. Given its modest standalone discriminatory performance and the selected nature of the histologically verified cohort, ΔCt should be considered an exploratory marker rather than a validated triage tool. Prospective validation is required to determine whether it provides incremental clinical value.
- 16 August 2023
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 29 (12) , 1606-1607
Re: ‘2020 list of human papillomavirus assays suitable for primary cervical cancer screening’ by Arbyn et al.
- 16 August 2023
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 29 (12) , 1606-1607
Re: ‘2020 list of human papillomavirus assays suitable for primary cervical cancer screening’ by Arbyn et al.
- Open Access
Emerging Mutations Potentially Related to SARS-CoV-2 Immune Escape: The Case of a Long-Term Patient
SARS-CoV-2 isolates from long-term COVID-19 patients play a significant role in understanding the mechanisms of infection and virus persistence. This study describes a SARS-CoV-2 isolate from a 53-year-old woman from Apulia (Italy), who was COVID-19 positive for approximately four months. In this paper we aimed to investigate any potential correlation between genetic mutations and clinical features of this case of infection. The viral isolate was assigned to lineage B.1.177.51 through whole-genome sequencing (WGS) and harbored a novel set of mutations on the Spike protein (V143D, del144/145 and E484K); furthermore, seroneutralization assays showed impaired response of the surveyed strain to BNT162b2 (Comirnaty) Pfizer/BioNTech vaccine-induced (average reduction of 70%) and convalescent sera (average reduction of 19.04%), when compared to VOC P.1. This study highlights the importance of genomic surveillance for the management of the COVID-19 pandemic, the relevance of monitoring of emerging SARS-CoV-2 mutations in all lineages, and the necessity of testing the response of emerging variants to available therapies and vaccines.
Open AccessEmerging Mutations Potentially Related to SARS-CoV-2 Immune Escape: The Case of a Long-Term Patient
SARS-CoV-2 isolates from long-term COVID-19 patients play a significant role in understanding the mechanisms of infection and virus persistence. This study describes a SARS-CoV-2 isolate from a 53-year-old woman from Apulia (Italy), who was COVID-19 positive for approximately four months. In this paper we aimed to investigate any potential correlation between genetic mutations and clinical features of this case of infection. The viral isolate was assigned to lineage B.1.177.51 through whole-genome sequencing (WGS) and harbored a novel set of mutations on the Spike protein (V143D, del144/145 and E484K); furthermore, seroneutralization assays showed impaired response of the surveyed strain to BNT162b2 (Comirnaty) Pfizer/BioNTech vaccine-induced (average reduction of 70%) and convalescent sera (average reduction of 19.04%), when compared to VOC P.1. This study highlights the importance of genomic surveillance for the management of the COVID-19 pandemic, the relevance of monitoring of emerging SARS-CoV-2 mutations in all lineages, and the necessity of testing the response of emerging variants to available therapies and vaccines.
- Open Access
- 20 March 2018
- Published by Springer Nature in Virology Journal
- Vol. 15 (1) , 48
Clinical validation of REALQUALITY RQ-HPV Screen according to the international guidelines for human papillomavirus DNA test requirements for cervical screening
According to international guidelines, HPV DNA tests represent a valid alternative to Pap Test for primary cervical cancer screening, provided that they guarantee balanced clinical sensitivity and specificity for cervical intraepithelial neoplasia grade 2 or more severe lesions. The aim of this study was to assess whether REALQUALITY RQ-HPV Screen, a new assay based on real time PCR that targets the E6-E7 region of 14 high-risk human papillomaviruses, meets the criteria for primary cervical cancer screening. As required by guidelines, a non-inferiority test was conducted to compare the clinical performance of the test under evaluation with that of a clinically validated reference test (Hybrid Capture 2, HC2). The reproducibility of the device was assessed as well. The clinical samples used to test the hypothesis of non-inferiority and to asses reproducibility comprised 910 and 536 cervical specimens respectively. All specimens were originating from a population-based screening cohort. The study demonstrates that both the clinical sensitivity and specificity of REALQUALITY RQ-HPV Screen are non-inferior to those of HC2. In addition, an adequate intra- and inter-laboratory reproducibility has been reached by the test. REALQUALITY RQ-HPV Screen fulfils all the requirements of the international guidelines and can be considered clinically validated for primary cervical cancer screening purposes.
- 20 March 2018
- Published by Springer Nature in Virology Journal
- Vol. 15 (1) , 48
Open AccessClinical validation of REALQUALITY RQ-HPV Screen according to the international guidelines for human papillomavirus DNA test requirements for cervical screening
According to international guidelines, HPV DNA tests represent a valid alternative to Pap Test for primary cervical cancer screening, provided that they guarantee balanced clinical sensitivity and specificity for cervical intraepithelial neoplasia grade 2 or more severe lesions. The aim of this study was to assess whether REALQUALITY RQ-HPV Screen, a new assay based on real time PCR that targets the E6-E7 region of 14 high-risk human papillomaviruses, meets the criteria for primary cervical cancer screening. As required by guidelines, a non-inferiority test was conducted to compare the clinical performance of the test under evaluation with that of a clinically validated reference test (Hybrid Capture 2, HC2). The reproducibility of the device was assessed as well. The clinical samples used to test the hypothesis of non-inferiority and to asses reproducibility comprised 910 and 536 cervical specimens respectively. All specimens were originating from a population-based screening cohort. The study demonstrates that both the clinical sensitivity and specificity of REALQUALITY RQ-HPV Screen are non-inferior to those of HC2. In addition, an adequate intra- and inter-laboratory reproducibility has been reached by the test. REALQUALITY RQ-HPV Screen fulfils all the requirements of the international guidelines and can be considered clinically validated for primary cervical cancer screening purposes.